Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Short-term Investments (2016 - 2025)

Cytokinetics (CYTK) has disclosed Short-term Investments for 16 consecutive years, with $759.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-term Investments changed N/A to $759.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $759.7 million, a N/A change, with the full-year FY2025 number at $759.7 million, changed N/A from a year prior.
  • Short-term Investments was $759.7 million for Q4 2025 at Cytokinetics, up from $737.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $964.8 million in Q3 2024 to a low of $313.1 million in Q2 2021.
  • A 5-year average of $599.0 million and a median of $501.8 million in 2023 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: soared 122.89% in 2021, then tumbled 42.27% in 2023.
  • Cytokinetics' Short-term Investments stood at $359.0 million in 2021, then soared by 99.74% to $717.0 million in 2022, then tumbled by 30.01% to $501.8 million in 2023, then soared by 92.27% to $964.8 million in 2024, then dropped by 21.26% to $759.7 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Short-term Investments are $759.7 million (Q4 2025), $737.1 million (Q3 2025), and $783.2 million (Q2 2025).